Sakar Healthcare has received first Marketing Authorization (MA) for an oncology injection product in the European Union (EU). This is a big achievement for Sakar to enter one of the most regulated pharmaceutical markets in the world and also marks its strategic shift to become a major player in oncology globally.
Global Oncology Exports Begin
On 21 April 2025, Sakar announced that it has received the first EU Marketing Authorization after submitting a meticulously prepared regulatory dossier as per EU guidelines. This is a key milestone for Sakar’s research driven, API integrated oncology formulation facility—a EU-GMP certified unit in Gujarat, India.
This will enable commercial distribution and export of the approved liquid oncology injection in the EU region. This approval also reflects the robustness of Sakar’s regulatory capabilities and growing recognition of Indian pharma in high barrier markets like Europe.
The company is not resting on its laurels. As per the same release, Sakar has 7 more oncology products in various stages of registration in EU which will get Marketing Authorization in next few months. This will lead to staggered product launches in European markets and increase Sakar’s revenue from international business.
Strategic Partnerships to Penetrate Market
Earlier this year, Sakar had announced strategic partnership with ACCORD Healthcare, a wholly owned subsidiary of Intas Pharmaceuticals, for manufacturing and supply of oncology products to EU, UK and emerging markets. This includes 7 oncology drugs—5 oral solids and 2 injectables—which are undergoing technology transfer at Sakar’s EU-GMP compliant manufacturing facility.
ACCORD is one of the top 3 oncology companies in EU, provides an established commercial infrastructure, giving Sakar access to hospitals and pharmacies in 45 countries. This partnership will give Sakar faster market access and also reflects the confidence in Sakar’s manufacturing and quality capabilities.
Multi-Regional Licensing Agreements Expand Global Reach
Sakar recently signed nine licensing agreements across Nordic countries, Central and Eastern Europe, and South America. Countries covered are:
- Nordics: Denmark, Sweden, Norway, Iceland, Finland
- CEE: Poland, Czech Republic, Hungary, Slovakia, Romania, Bulgaria
- South America: Mexico, Colombia, Paraguay, Bolivia, Costa Rica
Seven more agreements are in final stages of negotiation covering EU big four (Germany, France, Italy, Spain) and Latin America. These will further cement Sakar’s global oncology export plan and visibility.
Strong Numbers Despite Volatility
Despite a 38% fall in the stock over the last one year, Sakar shares have risen 21% in the last month, indicating renewed interest. The Intas partnership announcement pushed the stock up 4% intraday in February 2025.
On the numbers front, Sakar has done well:
- Revenue Growth: 16.6% YoY (Q3 FY24 to Q3 FY25), from INR 37.23 Cr to INR 43.4 Cr
- Net Profit: 117.4% YoY, from INR 2.07 Cr to INR 4.5 Cr
While EPS has been declining at 1.7% CAGR over five years, the stock has risen 400% over the same period, indicating investor confidence in long term growth.
A Technological Edge: Flow Chemistry & Advanced R&D Labs
Sakar Healthcare’s momentum is backed by continuous investments in innovation. The company has set up research laboratories—R&D, ADL (Analytical Development Lab), F&D (Formulation Development)—as part of a fully integrated oncology manufacturing ecosystem.
The facility has OEL-4 compliant equipment, continuous flow chemistry systems and machines from industry leaders in Belgium, Italy, China and UK. Flow chemistry reduces 90% energy and solvent waste, Sakar’s commitment to sustainable pharma manufacturing.This forward looking investment has already given two R&D project contracts abroad.
Sakar Healthcare Post-IPO Performance
Sakar Healthcare launched its IPO on 30 September 2016 on NSE Emerge. Sakar Healthcare IPO was a bookbuilding issue of INR 14.81 crore. The IPO recorded a lacklustre listing of 4.3%. However, the IPO delivered a multibagger returns of 788% and reached its all-time high of INR 439.30 per share on 25 January 2024. Currently, it is trading with a correction of 40%, at INR 313 per share. Notably, shares of Sakar Healthcare surged over 52% in in just 20 days in the month of April, signalling the vote of confidence in the investors.
Conclusion
Sakar Healthcare’s EU Marketing Authorization in hand, international collaborations growing, product registrations expanding and technologically advanced manufacturing and research setup, Sakar Healthcare is at an inflection point.
Though the stock has been volatile recently, long term indicators— revenue growth, global regulatory approvals, partnerships with top pharma companies—suggests a company on the verge of being a global player in oncology pharma.
Investors looking to play Indian pharma’s global story would do well to watch Sakar Healthcare’s execution over the next 12-24 months. With more EU approvals coming up and commercial supply chains being set up across the globe, Sakar’s transformation from a domestic CDMO to a global oncology brand is no more a question of if—but when.
For more details related to IPO GMP, SEBI IPO Approval, and Live Subscription stay tuned to IPO Central.